Press Briefing 1 - Breast Cancer
Papers presented & Comment Nadia Harbeck, Munich (webcasts shown below):
- LBA1_PR - IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) More INFO: Immunotherapy achieving improved survival in triple-negative breast cancer
- LBA2_PR - Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2_) advanced breast cancer (ABC): Analyses from PALOMA-3 More INFO: First trial to show a benefit with PI3K inhibitor combined with endocrine therapy in patients with HR+ HER2 advanced breast cancer
- LBA3_PR - Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial More INFO: Treatment with CDK4/6 inhibitor in HR+ HER2- advanced breast cancer after hormonal therapy
- Comment Nadia Harbeck, Munich